Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

E. J. van Helden; S. G. Elias; S. L. Gerritse; S. C. van Es; E. Boon; M. C. Huisman; N. C. T. van Grieken; H. Dekker; G. A. M. S. van Dongen; D. J. Vugts; R. Boellaard; C. M. L. van Herpen; E. G. E. de Vries; W. J. G. Oyen; A. H. Brouwers; H. M. W. Verheul; O. S. Hoekstra; C. W. Menke-van der Houven van Oordt

doi:10.1007/s00259-020-04908-6

Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

E. J. van Helden, S. G. Elias, S. L. Gerritse, S. C. van Es, E. Boon, M. C. Huisman, N. C. T. van Grieken, H. Dekker, G. A. M. S. van Dongen, D. J. Vugts, R. Boellaard, C. M. L. van Herpen, E. G. E. de Vries, W. J. G. Oyen, A. H. Brouwers, H. M. W. Verheul, O. S. Hoekstra, C. W. Menke-van der Houven van Oordt^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Citation (Scopus)

7 Downloads (Pure)

Original language	English
Pages (from-to)	2481-2481
Number of pages	1
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	47
Issue number	10
DOIs	https://doi.org/10.1007/s00259-020-04908-6
Publication status	Published - Sep-2020

Access to Document

10.1007/s00259-020-04908-6

Correction to_ [89Zr]Zr-cetuximab PET_CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancerFinal publisher's version, 93.3 KBLicence: Taverne

Cite this

van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S., & Menke-van der Houven van Oordt, C. W. (2020). Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 47(10), 2481-2481. https://doi.org/10.1007/s00259-020-04908-6

van Helden, E. J. ; Elias, S. G. ; Gerritse, S. L. ; van Es, S. C. ; Boon, E. ; Huisman, M. C. ; van Grieken, N. C. T. ; Dekker, H. ; van Dongen, G. A. M. S. ; Vugts, D. J. ; Boellaard, R. ; van Herpen, C. M. L. ; de Vries, E. G. E. ; Oyen, W. J. G. ; Brouwers, A. H. ; Verheul, H. M. W. ; Hoekstra, O. S. ; Menke-van der Houven van Oordt, C. W. / Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. In: European Journal of Nuclear Medicine and Molecular Imaging. 2020 ; Vol. 47, No. 10. pp. 2481-2481.

@article{da94b5d88ca84c529158c5c276ad65c6,

title = "Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer",

author = "{van Helden}, {E. J.} and Elias, {S. G.} and Gerritse, {S. L.} and {van Es}, {S. C.} and E. Boon and Huisman, {M. C.} and {van Grieken}, {N. C. T.} and H. Dekker and {van Dongen}, {G. A. M. S.} and Vugts, {D. J.} and R. Boellaard and {van Herpen}, {C. M. L.} and {de Vries}, {E. G. E.} and Oyen, {W. J. G.} and Brouwers, {A. H.} and Verheul, {H. M. W.} and Hoekstra, {O. S.} and {Menke-van der Houven van Oordt}, {C. W.}",

year = "2020",

month = sep,

doi = "10.1007/s00259-020-04908-6",

language = "English",

volume = "47",

pages = "2481--2481",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "SPRINGER",

number = "10",

}

van Helden, EJ, Elias, SG, Gerritse, SL, van Es, SC, Boon, E, Huisman, MC, van Grieken, NCT, Dekker, H, van Dongen, GAMS, Vugts, DJ, Boellaard, R, van Herpen, CML, de Vries, EGE, Oyen, WJG, Brouwers, AH, Verheul, HMW, Hoekstra, OS & Menke-van der Houven van Oordt, CW 2020, 'Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer', European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. 10, pp. 2481-2481. https://doi.org/10.1007/s00259-020-04908-6

Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. / van Helden, E. J.; Elias, S. G.; Gerritse, S. L.; van Es, S. C.; Boon, E.; Huisman, M. C.; van Grieken, N. C. T.; Dekker, H.; van Dongen, G. A. M. S.; Vugts, D. J.; Boellaard, R.; van Herpen, C. M. L.; de Vries, E. G. E.; Oyen, W. J. G.; Brouwers, A. H.; Verheul, H. M. W.; Hoekstra, O. S.; Menke-van der Houven van Oordt, C. W.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, No. 10, 09.2020, p. 2481-2481.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

AU - van Helden, E. J.

AU - Elias, S. G.

AU - Gerritse, S. L.

AU - van Es, S. C.

AU - Boon, E.

AU - Huisman, M. C.

AU - van Grieken, N. C. T.

AU - Dekker, H.

AU - van Dongen, G. A. M. S.

AU - Vugts, D. J.

AU - Boellaard, R.

AU - van Herpen, C. M. L.

AU - de Vries, E. G. E.

AU - Oyen, W. J. G.

AU - Brouwers, A. H.

AU - Verheul, H. M. W.

AU - Hoekstra, O. S.

AU - Menke-van der Houven van Oordt, C. W.

PY - 2020/9

Y1 - 2020/9

U2 - 10.1007/s00259-020-04908-6

DO - 10.1007/s00259-020-04908-6

M3 - Comment/Letter to the editor

VL - 47

SP - 2481

EP - 2481

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

IS - 10

ER -